Contribution of alpha‐synuclein pathology to cerebral glucose metabolism in patients with amnestic MCI
αSyn pathology can be detected in vivo by CSF αSyn SAA. We investigated the FDG PET pattern in aMCI patients with CSF αSyn SAA positivity. αSyn+ aMCI showed a marked brain hypometabolism in AD and DLB typical regions.
Authors
- Samir Abu‐Rumeileh (ORCID: https://orcid.org/0000-0003-0631-8506)
- Eric M. Reiman (ORCID: https://orcid.org/0000-0002-0705-3696)
- G Arajyan
- Christopher M. Weise
- Markus Otto (ORCID: https://orcid.org/0000-0003-4273-4267)
Institutions
- Alzheimer's Association (US)
- Translational Genomics Research Institute (US)
- University of Arizona (US)
- Banner Health (US)
- Banner Alzheimer’s Institute
- Arizona Alzheimer’s Consortium
- Arizona State University (US)
- Martin Luther University Halle-Wittenberg (DE)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2024-08-23
- DOI
- https://doi.org/10.1002/alz.14151
- Citations
- 3
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 1.16
Funders
- U.S. Department of Defense
- Alzheimer's Association
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Biogen
- University of Southern California
- Meso Scale Diagnostics
- Alzheimer's Disease Neuroimaging Initiative
- BioClinica
- Novartis Pharmaceuticals Corporation
- Northern California Institute for Research and Education
- Bundesministerium für Bildung und Forschung
- Eisai
- Servier
- H. Lundbeck A/S
- IXICO
- National Institutes of Health
- Genentech
- Canadian Institutes of Health Research